Eotaxin seems to promote a pro-inflammatory/pro-lipogenic phenotype of hepatocytes in vitro, whereas its deletion (ccl11−/− mice) or its blockade by neutralizing antibody or pharmacological inhibition of its receptor, CCR3, attenuated NAFLD in the above mouse models [160]. Here, CCR3 is linked to metabolic dysfunction-associated steatotic liver disease.